CEO Interview on Phase 2 Stroke and TBI Study AGN.c AGNPF is the world’s first company to investigate DMT for both the treatment of stroke and traumatic brain injury (global stroke treatment market expected to Reach a Value of $15B by the Year 2027) and took a big step as they completed dosing of the third and planned final cohort in its escalating dose Phase 1 clinical study of DMT.
AGN plans to publish the data from the study in an upcoming issue of a peer reviewed, scientific publication.
The second part of the study will include dosing subjects for 6 hours with repeated administrations over a two-week period which can be used in its first Phase 2 study for stroke and TBI.
More in this interview w/ the CEO
https://www.youtube.com/watch?v=XRlhyHSAEaA&embeds_referring_euri=https%3A%2F%2Fceo.ca%2F&source_ve_path=Mjg2NjY&feature=emb_logo